{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:10:24Z","timestamp":1793254224735,"version":"4.5.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,18]],"date-time":"2022-12-18T00:00:00Z","timestamp":1671321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,12,18]],"date-time":"2022-12-18T00:00:00Z","timestamp":1671321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s40120-022-00428-7","type":"journal-article","created":{"date-parts":[[2022,12,18]],"date-time":"2022-12-18T02:02:16Z","timestamp":1671328936000},"page":"11-23","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["The Early Diagnosis of Alzheimer\u2019s Disease: A Patient-Centred Conversation with the Care Team"],"prefix":"10.1007","volume":"12","author":[{"given":"Ziad","family":"Nasreddine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Garibotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Kyaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Padovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,18]]},"reference":[{"key":"428_CR1","doi-asserted-by":"publisher","unstructured":"Alzheimer\u2019s Association. 2020 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2020;16(3):391\u2013460. https:\/\/doi.org\/10.1002\/alz.12068.","DOI":"10.1002\/alz.12068"},{"key":"428_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12877-020-1493-4","volume":"20","author":"A Rosenberg","year":"2020","unstructured":"Rosenberg A, Coley N, Soulier A, et al. Experiences of dementia and attitude towards prevention: a qualitative study among older adults participating in a prevention trial. BMC Geriatr. 2020;20:1. https:\/\/doi.org\/10.1186\/s12877-020-1493-4.","journal-title":"BMC Geriatr"},{"key":"428_CR3","unstructured":"Hutchings R, Carter D, Bennett K. Dementia\u2014the true cost: fixing the care crisis. London: Alzheimer\u2019s Society; 2018."},{"issue":"3","key":"428_CR4","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jalz.2019.01.010","volume":"15","author":"Alzheimer's Association","year":"2019","unstructured":"Alzheimer's Association. Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2019;15(3):321\u201387. https:\/\/doi.org\/10.1016\/j.jalz.2019.01.010.","journal-title":"Alzheimers Dement"},{"key":"428_CR5","doi-asserted-by":"crossref","unstructured":"Alzheimer\u2019s Association. 2020 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2020;16(3):391\u2013460.","DOI":"10.1002\/alz.12068"},{"key":"428_CR6","unstructured":"Alzheimer Europe. Dementia in Europe yearbook 2019. https:\/\/www.alzheimer-europe.org\/sites\/default\/files\/alzheimer_europe_dementia_in_europe_yearbook_2019.pdf. Accessed 9 Dec 2022."},{"key":"428_CR7","unstructured":"Wimo A, J\u00f6nsson L, Gustavsson A. Cost of illness and burden of dementia in Europe\u2014Prognosis to 2030. Luxembourg: Alzheimer Europe; 2013."},{"key":"428_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.592302","volume":"11","author":"JE Galvin","year":"2020","unstructured":"Galvin JE, Aisen P, Langbaum JB, et al. Early stages of Alzheimer\u2019s disease: evolving the care team for optimal patient management. Front Neurol. 2020;11: 592302. https:\/\/doi.org\/10.3389\/fneur.2020.592302.","journal-title":"Front Neurol"},{"issue":"3","key":"428_CR9","doi-asserted-by":"publisher","first-page":"371","DOI":"10.14283\/jpad.2021.23","volume":"8","author":"AP Porsteinsson","year":"2021","unstructured":"Porsteinsson AP, Isaacson RS, Knox S, Sabbagh MN, Rubino I. Diagnosis of early Alzheimer\u2019s disease: clinical practice in 2021. J Prev Alzheimers Dis. 2021;8(3):371\u201386. https:\/\/doi.org\/10.14283\/jpad.2021.23.","journal-title":"J Prev Alzheimers Dis"},{"issue":"1","key":"428_CR10","doi-asserted-by":"publisher","first-page":"6189","DOI":"10.1101\/cshperspect.a006189","volume":"1","author":"A Serrano-Pozo","year":"2011","unstructured":"Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. 2011;1(1):6189. https:\/\/doi.org\/10.1101\/cshperspect.a006189.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"6","key":"428_CR11","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","volume":"20","author":"B Dubois","year":"2021","unstructured":"Dubois B, Villain N, Frisoni GB, et al. Clinical diagnosis of Alzheimer\u2019s disease: recommendations of the International Working Group. Lancet Neurol. 2021;20(6):484\u201396. https:\/\/doi.org\/10.1016\/S1474-4422(21)00066-1.","journal-title":"Lancet Neurol"},{"issue":"4","key":"428_CR12","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"428_CR13","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol Med. 2016;8(6):595\u2013608. https:\/\/doi.org\/10.15252\/emmm.201606210.","journal-title":"EMBO Mol Med"},{"issue":"1","key":"428_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41583-021-00533-w","volume":"23","author":"GB Frisoni","year":"2022","unstructured":"Frisoni GB, Altomare D, Thal DR, et al. The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nat Rev Neurosci. 2022;23(1):53\u201366. https:\/\/doi.org\/10.1038\/s41583-021-00533-w.","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"428_CR15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13195-017-0283-5","volume":"9","author":"PS Aisen","year":"2017","unstructured":"Aisen PS, Cummings J, Jack CR Jr, et al. On the path to 2025: understanding the Alzheimer\u2019s disease continuum. Alzheimers Res Ther. 2017;9(1):60. https:\/\/doi.org\/10.1186\/s13195-017-0283-5.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"428_CR16","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/s1474-4422(09)70299-6","volume":"9","author":"CR Jack Jr","year":"2010","unstructured":"Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade. Lancet Neurol. 2010;9(1):119\u201328. https:\/\/doi.org\/10.1016\/s1474-4422(09)70299-6.","journal-title":"Lancet Neurol"},{"issue":"6","key":"428_CR17","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jalz.2014.01.001","volume":"10","author":"F Jessen","year":"2014","unstructured":"Jessen F, Amariglio RE, van Boxtel M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer\u2019s disease. Alzheimers Dement. 2014;10(6):844\u201352. https:\/\/doi.org\/10.1016\/j.jalz.2014.01.001.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"428_CR18","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/S1474-4422(21)00066-1","volume":"20","author":"B Dubois","year":"2021","unstructured":"Dubois B, Villain N, Frisoni GB, et al. Clinical diagnosis of Alzheimer\u2019s disease: recommendations of the International Working Group. Lancet Neurol. 2021;20(6):484\u201396. https:\/\/doi.org\/10.1016\/S1474-4422(21)00066-1.","journal-title":"Lancet Neurol"},{"issue":"13","key":"428_CR19","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/jama.2019.2000","volume":"321","author":"GD Rabinovici","year":"2019","unstructured":"Rabinovici GD, Gatsonis C, Apgar C, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia. JAMA. 2019;321(13):1286\u201394. https:\/\/doi.org\/10.1001\/jama.2019.2000.","journal-title":"JAMA"},{"key":"428_CR20","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.trci.2019.02.008","volume":"5","author":"JE Gaugler","year":"2019","unstructured":"Gaugler JE, Bain LJ, Mitchell L, et al. Reconsidering frameworks of Alzheimer\u2019s dementia when assessing psychosocial outcomes. Alzheimers Dement (N Y). 2019;5:388\u201397. https:\/\/doi.org\/10.1016\/j.trci.2019.02.008.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"15","key":"428_CR21","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1212\/wnl.0000000000005303","volume":"90","author":"EM Arenaza-Urquijo","year":"2018","unstructured":"Arenaza-Urquijo EM, Vemuri P. Resistance vs resilience to Alzheimer disease: clarifying terminology for preclinical studies. Neurology. 2018;90(15):695\u2013703. https:\/\/doi.org\/10.1212\/wnl.0000000000005303.","journal-title":"Neurology"},{"issue":"10","key":"428_CR22","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/j.neuropsychologia.2009.03.004","volume":"47","author":"Y Stern","year":"2009","unstructured":"Stern Y. Cognitive reserve. Neuropsychologia. 2009;47(10):2015\u201328. https:\/\/doi.org\/10.1016\/j.neuropsychologia.2009.03.004.","journal-title":"Neuropsychologia"},{"key":"428_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/nu13114080","volume":"13","author":"LJ Dominguez","year":"2021","unstructured":"Dominguez LJ, Veronese N, Vernuccio L, et al. Nutrition, physical activity, and other lifestyle factors in the prevention of cognitive decline and dementia. Nutrients. 2021;13:11. https:\/\/doi.org\/10.3390\/nu13114080.","journal-title":"Nutrients"},{"issue":"6","key":"428_CR24","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1001\/jama.2018.21442","volume":"321","author":"JD Williamson","year":"2019","unstructured":"Williamson JD, Pajewski NM, Auchus AP, et al. Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA. 2019;321(6):553\u201361. https:\/\/doi.org\/10.1001\/jama.2018.21442.","journal-title":"JAMA"},{"issue":"11","key":"428_CR25","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1016\/j.jamda.2020.04.006","volume":"21","author":"JH Liang","year":"2020","unstructured":"Liang JH, Lu L, Li JY, et al. Contributions of modifiable risk factors to dementia incidence: a Bayesian network analysis. J Am Med Dir Assoc. 2020;21(11):1592\u20139. https:\/\/doi.org\/10.1016\/j.jamda.2020.04.006.","journal-title":"J Am Med Dir Assoc"},{"issue":"10284","key":"428_CR26","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer\u2019s disease. Lancet. 2021;397(10284):1577\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(20)32205-4.","journal-title":"Lancet"},{"issue":"11","key":"428_CR27","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/1099-1166(200011)15:11<1021::aid-gps234>3.0.co;2-6","volume":"15","author":"S Borson","year":"2000","unstructured":"Borson S, Scanlan J, Brush M, Vitaliano P, Dokmak A. The mini-cog: a cognitive \u201cvital signs\u201d measure for dementia screening in multi-lingual elderly. Int J Geriatr Psychiatry. 2000;15(11):1021\u20137. https:\/\/doi.org\/10.1002\/1099-1166(200011)15:11%3c1021::aid-gps234%3e3.0.co;2-6.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"6","key":"428_CR28","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1177\/1756285612455733","volume":"5","author":"B Sheehan","year":"2012","unstructured":"Sheehan B. Assessment scales in dementia. Ther Adv Neurol Disord. 2012;5(6):349\u201358. https:\/\/doi.org\/10.1177\/1756285612455733.","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"428_CR29","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695\u20139. https:\/\/doi.org\/10.1111\/j.1532-5415.2005.53221.x.","journal-title":"J Am Geriatr Soc"},{"issue":"8","key":"428_CR30","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jama.2019.22258","volume":"323","author":"CD Patnode","year":"2020","unstructured":"Patnode CD, Perdue LA, Rossom RC, et al. Screening for cognitive impairment in older adults: updated evidence report and systematic review for the US preventive services task force. JAMA. 2020;323(8):764\u201385. https:\/\/doi.org\/10.1001\/jama.2019.22258.","journal-title":"JAMA"},{"issue":"1 Suppl","key":"428_CR31","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1016\/j.jalz.2012.01.005","volume":"9","author":"MM Williams","year":"2013","unstructured":"Williams MM, Storandt M, Roe CM, Morris JC. Progression of Alzheimer\u2019s disease as measured by clinical dementia rating sum of boxes scores. Alzheimers Dement. 2013;9(1 Suppl):S39-44. https:\/\/doi.org\/10.1016\/j.jalz.2012.01.005.","journal-title":"Alzheimers Dement"},{"key":"428_CR32","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/978-0-387-79948-3_1791","volume-title":"Encyclopedia of clinical neuropsychology","author":"J Fish","year":"2011","unstructured":"Fish J. Alzheimer\u2019s disease cooperative study ADL scale. In: Kreutzer JS, DeLuca J, Caplan B, editors. Encyclopedia of clinical neuropsychology. New York: Springer; 2011. p. 111\u20132."},{"issue":"11","key":"428_CR33","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","volume":"141","author":"WG Rosen","year":"1984","unstructured":"Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer\u2019s disease. Am J Psychiatry. 1984;141(11):1356\u201364. https:\/\/doi.org\/10.1176\/ajp.141.11.1356.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"428_CR34","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, Mchugh PR. \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189\u201398. https:\/\/doi.org\/10.1016\/0022-3956(75)90026-6.","journal-title":"J Psychiatr Res"},{"issue":"1","key":"428_CR35","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s13670-018-0236-2","volume":"7","author":"JE Galvin","year":"2018","unstructured":"Galvin JE. Using Informant and performance screening methods to detect mild cognitive impairment and dementia. Curr Geriatr Rep. 2018;7(1):19\u201325. https:\/\/doi.org\/10.1007\/s13670-018-0236-2.","journal-title":"Curr Geriatr Rep"},{"issue":"1","key":"428_CR36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13195-020-00603-8","volume":"12","author":"AE Thomann","year":"2020","unstructured":"Thomann AE, Berres M, Goettel N, Steiner LA, Monsch AU. Enhanced diagnostic accuracy for neurocognitive disorders: a revised cut-off approach for the Montreal Cognitive Assessment. Alzheimers Res Ther. 2020;12(1):39. https:\/\/doi.org\/10.1186\/s13195-020-00603-8.","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"428_CR37","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/jgs.12742","volume":"62","author":"P Julayanont","year":"2014","unstructured":"Julayanont P, Brousseau M, Chertkow H, Phillips N, Nasreddine ZS. Montreal cognitive assessment memory index score (MoCA-MIS) as a predictor of conversion from mild cognitive impairment to Alzheimer\u2019s disease. J Am Geriatr Soc. 2014;62(4):679\u201384. https:\/\/doi.org\/10.1111\/jgs.12742.","journal-title":"J Am Geriatr Soc"},{"issue":"7","key":"428_CR38","doi-asserted-by":"publisher","first-page":"e21896","DOI":"10.1371\/journal.pone.0021896","volume":"6","author":"Y Cui","year":"2011","unstructured":"Cui Y, Liu B, Luo S, et al. Identification of conversion from mild cognitive impairment to Alzheimer\u2019s disease using multivariate predictors. PLoS ONE. 2011;6(7):e21896. https:\/\/doi.org\/10.1371\/journal.pone.0021896.","journal-title":"PLoS ONE"},{"key":"428_CR39","doi-asserted-by":"publisher","first-page":"6628036","DOI":"10.1155\/2021\/6628036","volume":"2021","author":"S Minhas","year":"2021","unstructured":"Minhas S, Khanum A, Alvi A, et al. Early MCI-to-AD conversion prediction using future value forecasting of multimodal features. Comput Intell Neurosci. 2021;2021:6628036. https:\/\/doi.org\/10.1155\/2021\/6628036.","journal-title":"Comput Intell Neurosci"},{"issue":"7","key":"428_CR40","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/wnl.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer\u2019s disease. Neurology. 1984;34(7):939\u201344. https:\/\/doi.org\/10.1212\/wnl.34.7.939.","journal-title":"Neurology"},{"key":"428_CR41","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fnins.2018.00025","volume":"12","author":"F Kametani","year":"2018","unstructured":"Kametani F, Hasegawa M. Reconsideration of amyloid hypothesis and tau hypothesis in Alzheimer\u2019s disease. Front Neurosci. 2018;12:25. https:\/\/doi.org\/10.3389\/fnins.2018.00025.","journal-title":"Front Neurosci"},{"key":"428_CR42","unstructured":"Whipple T. Has this man found the key to the Alzheimer\u2019s time bomb? https:\/\/www.thetimes.co.uk\/article\/has-this-man-found-the-key-to-the-alzheimers-time-bomb-nttt96f95. Accessed 9 Dec 2022."},{"issue":"4","key":"428_CR43","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimers Dement"},{"issue":"8","key":"428_CR44","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1474-4422(17)30159-X","volume":"16","author":"GB Frisoni","year":"2017","unstructured":"Frisoni GB, Boccardi M, Barkhof F, et al. Strategic roadmap for an early diagnosis of Alzheimer\u2019s disease based on biomarkers. Lancet Neurol. 2017;16(8):661\u201376. https:\/\/doi.org\/10.1016\/S1474-4422(17)30159-X.","journal-title":"Lancet Neurol"},{"issue":"7","key":"428_CR45","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1007\/s00259-021-05258-7","volume":"48","author":"A Leuzy","year":"2021","unstructured":"Leuzy A, Ashton NJ, Mattsson-Carlgren N, et al. 2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer\u2019s disease in the context of a structured 5-phase development framework. Eur J Nucl Med Mol Imaging. 2021;48(7):2121\u201339. https:\/\/doi.org\/10.1007\/s00259-021-05258-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"428_CR46","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s00259-020-05118-w","volume":"48","author":"EE Wolters","year":"2021","unstructured":"Wolters EE, Dodich A, Boccardi M, et al. Clinical validity of increased cortical uptake of [(18)F]flortaucipir on PET as a biomarker for Alzheimer\u2019s disease in the context of a structured 5-phase biomarker development framework. Eur J Nucl Med Mol Imaging. 2021;48(7):2097\u2013109. https:\/\/doi.org\/10.1007\/s00259-020-05118-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"428_CR47","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1148\/radiol.2020200028","volume":"298","author":"VL Villemagne","year":"2021","unstructured":"Villemagne VL, Barkhof F, Garibotto V, Landau SM, Nordberg A, van Berckel BNM. Molecular imaging approaches in dementia. Radiology. 2021;298(3):517\u201330. https:\/\/doi.org\/10.1148\/radiol.2020200028.","journal-title":"Radiology"},{"issue":"11","key":"428_CR48","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S1474-4422(20)30314-8","volume":"19","author":"G Chetelat","year":"2020","unstructured":"Chetelat G, Arbizu J, Barthel H, et al. Amyloid-PET and (18)F-FDG-PET in the diagnostic investigation of Alzheimer\u2019s disease and other dementias. Lancet Neurol. 2020;19(11):951\u201362. https:\/\/doi.org\/10.1016\/S1474-4422(20)30314-8.","journal-title":"Lancet Neurol"},{"issue":"4","key":"428_CR49","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nrneurol.2018.9","volume":"14","author":"VL Villemagne","year":"2018","unstructured":"Villemagne VL, Dor\u00e9 V, Burnham SC, Masters CL, Rowe CC. Imaging tau and amyloid-\u03b2 proteinopathies in Alzheimer disease and other conditions. Nat Rev Neurol. 2018;14(4):225\u201336. https:\/\/doi.org\/10.1038\/nrneurol.2018.9.","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"428_CR50","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1007\/s00259-020-04923-7","volume":"48","author":"EC Mormino","year":"2021","unstructured":"Mormino EC, Toueg TN, Azevedo C, et al. Tau PET imaging with 18F-PI-2620 in aging and neurodegenerative diseases. Eur J Nucl Med Mol Imaging. 2021;48(7):2233\u201344. https:\/\/doi.org\/10.1007\/s00259-020-04923-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"428_CR51","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1001\/archneur.61.3.378","volume":"61","author":"DA Bennett","year":"2004","unstructured":"Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol. 2004;61(3):378\u201384. https:\/\/doi.org\/10.1001\/archneur.61.3.378.","journal-title":"Arch Neurol"},{"issue":"6","key":"428_CR52","doi-asserted-by":"publisher","first-page":"e601","DOI":"10.1212\/wnl.0000000000006875","volume":"92","author":"R Ossenkoppele","year":"2019","unstructured":"Ossenkoppele R, Smith R, Ohlsson T, et al. Associations between tau, A\u03b2, and cortical thickness with cognition in Alzheimer disease. Neurology. 2019;92(6):e601\u201312. https:\/\/doi.org\/10.1212\/wnl.0000000000006875.","journal-title":"Neurology"},{"issue":"2","key":"428_CR53","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3390\/ph14020110","volume":"14","author":"CVML Jie","year":"2021","unstructured":"Jie CVML, Treyer V, Schibli R, Mu L. Tauvid\u2122: the first FDA-approved PET tracer for imaging tau pathology in Alzheimer\u2019s disease. Pharmaceuticals (Basel). 2021;14(2):110. https:\/\/doi.org\/10.3390\/ph14020110.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"428_CR54","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1602\/neurorx.1.2.213","volume":"1","author":"K Blennow","year":"2004","unstructured":"Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer\u2019s disease. NeuroRx. 2004;1(2):213\u201325. https:\/\/doi.org\/10.1602\/neurorx.1.2.213.","journal-title":"NeuroRx"},{"key":"428_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-019-0485-0","volume":"11","author":"O Hansson","year":"2019","unstructured":"Hansson O, Lehmann S, Otto M, Zetterberg H, Lewczuk P. Advantages and disadvantages of the use of the CSF amyloid \u03b2 (A\u03b2) 42\/40 ratio in the diagnosis of Alzheimer\u2019s disease. Alzheimers Res Ther. 2019;11:1. https:\/\/doi.org\/10.1186\/s13195-019-0485-0.","journal-title":"Alzheimers Res Ther"},{"key":"428_CR56","unstructured":"US Food and Drug Administration. FDA permits marketing for new test to improve diagnosis of Alzheimer\u2019s disease. 2022. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-permits-marketing-new-test-improve-diagnosis-alzheimers-disease. Accessed 16 May 2022."},{"issue":"1","key":"428_CR57","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12182","volume":"13","author":"EAJ Willemse","year":"2021","unstructured":"Willemse EAJ, Tijms BM, van Berckel BNM, et al. Comparing CSF amyloid-beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status. Alzheimers Dement. 2021;13(1):e12182. https:\/\/doi.org\/10.1002\/dad2.12182.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"428_CR58","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3233\/jad-150342","volume":"48","author":"P Lewczuk","year":"2015","unstructured":"Lewczuk P, Kornhuber J, Toledo JB, et al. Validation of the Erlangen score algorithm for the prediction of the development of dementia due to Alzheimer\u2019s disease in pre-dementia subjects. J Alzheimers Dis. 2015;48(2):433\u201341. https:\/\/doi.org\/10.3233\/jad-150342.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"428_CR59","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/alzrt267","volume":"6","author":"S Lehmann","year":"2014","unstructured":"Lehmann S, Dumurgier J, Schraen S, et al. A diagnostic scale for Alzheimer\u2019s disease based on cerebrospinal fluid biomarker profiles. Alzheimers Res Ther. 2014;6(3):38. https:\/\/doi.org\/10.1186\/alzrt267.","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"428_CR60","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jalz.2015.08.003","volume":"12","author":"FH Duits","year":"2016","unstructured":"Duits FH, Martinez-Lage P, Paquet C, et al. Performance and complications of lumbar puncture in memory clinics: results of the multicenter lumbar puncture feasibility study. Alzheimers Dement. 2016;12(2):154\u201363. https:\/\/doi.org\/10.1016\/j.jalz.2015.08.003.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"428_CR61","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.3233\/jad-170784","volume":"62","author":"CE Teunissen","year":"2018","unstructured":"Teunissen CE, Chiu MJ, Yang CC, et al. Plasma amyloid-\u03b2 (A\u03b242) correlates with cerebrospinal fluid A\u03b242 in Alzheimer\u2019s disease. J Alzheimers Dis. 2018;62(4):1857\u201363. https:\/\/doi.org\/10.3233\/jad-170784.","journal-title":"J Alzheimers Dis"},{"issue":"7","key":"428_CR62","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1007\/s00259-021-05253-y","volume":"48","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Leuzy A, Karikari TK, et al. The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. Eur J Nucl Med Mol Imaging. 2021;48(7):2140\u201356. https:\/\/doi.org\/10.1007\/s00259-021-05253-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"428_CR63","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.neubiorev.2020.12.003","volume":"121","author":"Y Mimura","year":"2021","unstructured":"Mimura Y, Nishida H, Nakajima S, et al. Neurophysiological biomarkers using transcranial magnetic stimulation in Alzheimer\u2019s disease and mild cognitive impairment: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2021;121:47\u201359. https:\/\/doi.org\/10.1016\/j.neubiorev.2020.12.003.","journal-title":"Neurosci Biobehav Rev"},{"key":"428_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101361","volume":"69","author":"YJ Ge","year":"2021","unstructured":"Ge YJ, Xu W, Ou YN, et al. Retinal biomarkers in Alzheimer\u2019s disease and mild cognitive impairment: a systematic review and meta-analysis. Ageing Res Rev. 2021;69:101361. https:\/\/doi.org\/10.1016\/j.arr.2021.101361.","journal-title":"Ageing Res Rev"},{"issue":"1","key":"428_CR65","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41746-019-0084-2","volume":"2","author":"LC Kourtis","year":"2019","unstructured":"Kourtis LC, Regele OB, Wright JM, Jones GB. Digital biomarkers for Alzheimer\u2019s disease: the mobile\/wearable devices opportunity. NPJ Digit Med. 2019;2(1):9. https:\/\/doi.org\/10.1038\/s41746-019-0084-2.","journal-title":"NPJ Digit Med"},{"key":"428_CR66","unstructured":"Global Coalition on Aging. Dementia Innovation Readiness Index. 2017. https:\/\/www.alzint.org\/u\/gcoa-adi-dementia-index.pdf. Accessed 9 Dec 2022."},{"issue":"3","key":"428_CR67","first-page":"2","volume":"8","author":"JP Hlavka","year":"2019","unstructured":"Hlavka JP, Mattke S, Liu JL. Assessing the preparedness of the health care system infrastructure in six European countries for an Alzheimer\u2019s treatment. Rand Health Quart. 2019;8(3):2.","journal-title":"Rand Health Quart"},{"issue":"12","key":"428_CR68","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1001\/jamaneurol.2020.2734","volume":"77","author":"JD Grill","year":"2020","unstructured":"Grill JD, Raman R, Ernstrom K, et al. Short-term psychological outcomes of disclosing amyloid imaging results to research participants who do not have cognitive impairment. JAMA Neurol. 2020;77(12):1504\u201313. https:\/\/doi.org\/10.1001\/jamaneurol.2020.2734.","journal-title":"JAMA Neurol"},{"issue":"1","key":"428_CR69","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12150","volume":"13","author":"CM Erickson","year":"2021","unstructured":"Erickson CM, Chin NA, Johnson SC, Gleason CE, Clark LR. Disclosure of preclinical Alzheimer\u2019s disease biomarker results in research and clinical settings: why, how, and what we still need to know. Alzheimers Dement (Amst). 2021;13(1):e12150. https:\/\/doi.org\/10.1002\/dad2.12150.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"2","key":"428_CR70","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/gps.5427","volume":"36","author":"KS Frederiksen","year":"2021","unstructured":"Frederiksen KS, Nielsen TR, Appollonio I, et al. Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: a European Alzheimer\u2019s Disease Consortium survey. Int J Geriatr Psychiatry. 2021;36(2):324\u201333. https:\/\/doi.org\/10.1002\/gps.5427.","journal-title":"Int J Geriatr Psychiatry"},{"issue":"5","key":"428_CR71","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1136\/jnnp.69.5.574","volume":"69","author":"B Meiser","year":"2000","unstructured":"Meiser B, Dunn S. Psychological impact of genetic testing for Huntington\u2019s disease: an update of the literature. J Neurol Neurosurg Psychiatry. 2000;69(5):574. https:\/\/doi.org\/10.1136\/jnnp.69.5.574.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"428_CR72","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/978-3-030-77904-7_4","volume":"2","author":"KS Frederiksen","year":"2021","unstructured":"Frederiksen KS, Waldemar G. Disclosure of diagnosis in MCI and dementia. Manag Patients Dement. 2021;2:57\u201372.","journal-title":"Manag Patients Dement"},{"issue":"s1","key":"428_CR73","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.3233\/JAD-179901","volume":"64","author":"J Cummings","year":"2018","unstructured":"Cummings J, Ritter A, Zhong K. Clinical trials for disease-modifying therapies in Alzheimer\u2019s disease: a primer, lessons learned, and a blueprint for the future. J Alzheimers Dis. 2018;64(s1):S3\u201322. https:\/\/doi.org\/10.3233\/JAD-179901.","journal-title":"J Alzheimers Dis"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00428-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-022-00428-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-022-00428-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T10:27:20Z","timestamp":1673519240000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-022-00428-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,18]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["428"],"URL":"https:\/\/doi.org\/10.1007\/s40120-022-00428-7","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,18]]},"assertion":[{"value":"3 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}